

## **Microsize and AFT Pharmaceuticals Limited Expand CDMO Relationship for MAXIGESIC®/COMBOGESIC® Commercial Supply with Investments in Capacity Expansion**

**Newly FDA Approved MAXIGESTIC/COMBOGESIC® Non-Opioid Analgesic, Drives Additional CAPEX Investment for the Blending & Micronization Services Microsize Provides.**

**March 1st, 2024 – Quakertown PA** – Microsize today announced the signing of a long-term supply agreement with AFT Pharmaceuticals Limited to provide blending and micronization services for the active pharmaceutical ingredients (APIs) used in both the MAXIGESIC/COMBOGESIC® oral solid dose product lines. The eight year supply agreement includes a joint CAPEX investment for commercial scale continuous blending and micronization equipment trains capable of supplying the drug product intermediate (DPI) to several world markets including the US and EU. MAXIGESIC/COMBOGESIC represents a major advancement in pain management which includes rapid onset and powerful analgesic relief without the need for opioids.

TJ Higley, CEO of Microsize, commented: “We are excited to have been chosen as the commercial partner to supply the blended/micronized drug product intermediate (DPI) for AFT. Our approach of using continuous blending technologies along with the largest micronization mills in the pharmaceutical space, make our offering ideal for this product’s expected annual volumes and supply chain requirements. The collaboration between our companies since the early days of formulation development through clinical batches has been nothing short of spectacular and we look forward to continued expansion of this relationship.” Dr Hartley Atkinson, CEO of AFT commented “we are very pleased to work with Microsize who have considerable expertise in micronization technology which is crucial for the new rapid release Maxigesic/Combogesic formulation”

### **About AFT:**

AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. The product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. The business model is to develop and in-license products for sale by their own dedicated sales teams in home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit website [www.aftpharm.com](http://www.aftpharm.com)

**About Microsize:**

For over 30 years, Microsize has been a pioneer in enhancing dissolution and bioavailability of Active Pharmaceutical Ingredients (API's) and functional excipients via particle size reduction technologies including milling, micronization and classification. Operating from 100,000 square feet in US-based, state-of-the-art, FDA-inspected GMP facilities, Microsize has the experience and capabilities to rapidly develop, scale up, and process API's and excipients ranging from grams to multi-metric tons, including highly potent compounds ("HPAPI's"). Microsize is THE partner of choice from small biotechs to big pharma to CDMO's, and is recognized for its speed, responsiveness, and high customer-touch business model. When it comes to your toughest particle size challenges, *Think Big.....Think Microsize!* Visit us at [www.microsize.com](http://www.microsize.com).

<b>Microsize Contact:</b>	
---------------------------	--

TJ Higley

CEO

Microsize

Email: [tjhigley@microsize.com](mailto:tjhigley@microsize.com)

phone: 215-536-5605

#####